The differential effect of CB1 receptors on the discharge of afferent and efferent fibres supplying the rat jejunum

Neurogastroenterology and Motility

Volumn 23, Issue 6, 2011, Pages

  Donovan, J ^a   Grundy, D ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Afferent; Cannabinoids; Efferent; Neuron; Nutrition; Sensory

Indexed keywords

ADRENIC ACID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; DOCOSATETRAENYLETHANOLAMIDE; HEXAMETHONIUM; UNCLASSIFIED DRUG; CANNABINOID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIET RESTRICTION; EFFERENT NERVE; GASTROINTESTINAL TRACT FUNCTION; INTESTINE INNERVATION; INTESTINE PRESSURE; JEJUNUM; MALE; NERVE CONDUCTION; NONHUMAN; POSTGANGLIONIC NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR POTENTIAL; RECEPTOR SENSITIVITY; SENSORY NERVE; VAGOTOMY; ANIMAL; BLOOD PRESSURE; DRUG EFFECT; DRUG POTENTIATION; INNERVATION; METABOLISM; PHYSIOLOGY; SENSORY NERVE CELL; WISTAR RAT;

ANIMALS; BLOOD PRESSURE; CANNABINOIDS; JEJUNUM; MALE; NEURONS, AFFERENT; NEURONS, EFFERENT; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1;

EID: 79955921999     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01693.x     Document Type: Article

References (58)

1. Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001; 134: 1151-4.
2. Soria-Gómez E, Matias I, Rueda-Orozco PE et al. Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. Br J Pharmacol 2007; 151: 1109-16.
3. Gomez R, Navarro M, Ferrer B et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-7.
4. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 2004; 24: 2708-15.
5. Hornby PJ, Prouty SM. Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol 2004; 141: 1335-45.
6. Landi M, Croci T, Rinaldi-Carmona M, Maffrand J, Le Fur G, Manara L. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB1 receptors. Eur J Pharmacol 2002; 450: 77-83.
7. Pertwee R, Fernando S, Nash J, Coutts A. Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br J Pharmacol 1996; 118: 2199-205.
8. Pinto L, Izzo AA, Cascio MG et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 2002; 123: 227-34.
9. Kulkarni-Narla A, Brown D. Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 2000; 302: 73-80.
10. MacNaughton WK, Van Sickle MD, Keenan CM, Cushing K, Mackie K, Sharkey KA. Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. Am J Physiol Gastrointest Liver Physiol 2004; 286: G863-71.
11. Kelly SJ, Jhaveri MD, Sagar DR, Kendall DA, Chapman V. Activation of peripheral cannabinoid CB1 receptor inhibits mechanically evoked response of spinal neurons in noninflamed rats and rats with hindpaw inflammation. Eur J Neurosci 2003; 18: 2239-43.
12. Nackley AG, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses spinal fos protein expression and pain behaviour in a rat model of inflammation. Neuroscience 2003; 119: 747-57.
13. Nackley AG, Zyonok AG, Makriyannis A, Hohmann AG. Activation of cannabinoid CB2 receptors suppresses C-fibre responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol 2004; 92: 3562-74.
14. Ross RA, Coutts AA, McFarlane SM et al. Actions of cannabinoid receptor ligands on rat cultured sensory neurons: implications for antinociception. Neuropharmacology 2001; 40: 221-32.
15. Sagar DR, Kelly S, Millns PJ, O'Shaughnessey CT, Kendall DA, Chapman V. Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 2005; 22: 371-9.
16. Burdyga G, de Lartigue G, Raybould HE et al. Cholecystokinin regulates expression of Y2 receptors in vagal afferent neurons serving the stomach. J Neurosci 2008; 28: 11583-92.
17. Burdyga G, Varro A, Dimaline R, Thompson DG, Dockray GJ. Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype. Am J Physiol Gastrointest Liver Physiol 2010; 299: G63-9.
18. Burdyga G, Varro A, Dimaline R, Thompson DG, Dockray GJ. Feeding-dependent depression of melanin-concentrating hormone and melanin-concentrating hormone receptor-1 expression in vagal afferent neurones. Neuroscience 2006; 137: 1405-15.
19. Niederhoffer N, Szabo B. Cannabinoids cause central sympathoexcitation and bradycardia in rabbits. J Pharmacol Exp Ther 2000; 294: 707-13.
20. Varga K, Lake K, Martin BR, Kunos G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 1995; 278: 279-83.
21. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550-7.
22. Barg J, Fride E, Hanus L et al. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur J Pharmacol 1995; 287: 145-52.
23. Hanus L, Gopher A, Almog S, Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 1993; 36: 3032-4.
24. Pertwee R, Griffin G, Hanug L, Mechoulam R. Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. Eur J Pharmacol 1994; 259: 115-20.
25. Lawrence DK, Gill WE. The Effects of delta1-tetrahydrocannabinol and other cannabinoids on spin-labeled liposomes and their relationship to mechanisms of general anesthesia. Mol Pharmacol 1975; 11: 595-602.
26. Mechoulam R, Hanus L, Martin BR. Search for endogenous ligands of the cannabinoid receptor. Biochem Pharmacol 1994; 48: 1537-44.
27. Razdan RK. Structure-activity relationships in cannabinoids. Pharmacol Rev 1986; 38: 75-149.
28. Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G. Mechanism of the hypotensive action of anandamide in anesthetised rats. Hypertension 1996; 28: 682-6.
29. Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 1996; 118: 2023-8.
30. Lake KD, Compton DR, Varga K, Martin BR, Kunos G. Cannabinoid-induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther 1997; 281: 1030-7.
31. Ledent C, Valverde O, Cossu G et al. Unresponsiveness to cannabinoids and reduced addictive effect of opiates in CB1 receptor knockout mice. Science 1999; 283: 401.
32. Zygmunt PM, Petersson J, Andersson DA et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400: 452-7.
33. Jarai Z, Wagner JA, Varga K et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 1999; 96: 14136-41.
34. Wagner JA, Varga K, Jarai Z, Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 1999; 33: 429-34.
35. Mukhopadhyay S, Chapnick BM, Howlett AC. Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol Heart Circ Physiol 2002; 282: H2046-54.
36. Zygmunt PM, Hogestatt ED, Waldeck K, Edwards G, Kirkup AJ, Weston AH. Studies on the effects of anandamide in rat hepatic artery. Br J Pharmacol 1997; 122: 1679-86.
37. Gebremedhin D, Lange AR, Campbell WB, Hillard CJ, Harder DR. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type calcium channel current. Am J Physiol Heart Circ Physiol 1999; 276: 2085-93.
38. Deutsch DG, Goligorsky MS, Schmid PC et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 1997; 100: 1538-46.
39. Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K. Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun 1998; 243: 838-43.
40. Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S. Localization of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 2002; 448: 410-22.
41. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 1999; 92: 1171-5.
42. MacNaughton W, Van Sickle M, Keenan C, Cushing K, Mackie K, Sharkey K. Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. Am J Physiol Gastrointest Liver Physiol 2003; 286: G863-71.
43. Partosoedarso E, Abrahams T, Scullion R, Moerschbaecher J, Hornby P. Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol 2003; 550: 149-58.
44. Madsen AN, Jelsing J, van de Wall EHEM, Vrang N, Larsen PJ, Schwartz GJ. Rimonabant-induced anorexia in rodents is not mediated by vagal or sympathetic gut afferents. Neurosci Lett 2009; 449: 20-3.
45. Pertwee R. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009; 156: 397-411.
46. Hillsley K, McCaul C, Aerssens J et al. Activation of the cannabinoid 2 (CB2) receptor inhibits murine mesenteric afferent nerve activity. Neurogastroenterol Motil 2007; 19: 769-77.
47. Yüce B, Kemmer M, Qian G et al. Cannabinoid 1 receptors modulate intestinal sensory and motor function in rat. Neurogastroenterol Motil 2010; 22: 672-e205.
48. McVey DC, Schmid PC, Schmid HH, Vigna SR. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). J Pharmacol Exp Ther 2003; 304: 713-22.
49. Millns P, Chapman V, Kendall D. Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurons. BJP 2001; 132: 969-71.
50. Ross RA. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 2003; 140: 790-801.
51. Glass M, Felder CC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 1997; 17: 5327-33.
52. Maneuf YP, Brotchie JM. Paradoxical action of the cannabinoid WIN55, 212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 1997; 120: 1397-8.
53. Sulcova E, Mechoulam R, Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 1998; 59: 347-52.
54. Michaelis M, Boczek-Funcke A, Habler H-J, Janig W. Responses of lumbar vasoconstrictor neurons supplying different vascular beds to graded baroreceptor stimuli in the cat. J Auton Nerv Syst 1993; 42: 241-50.
55. Seagard JL, Dean C, Patel S et al. Anandamide content and interaction of endocannabinoid/GABA modulatory effects in the NTS on baroreflex-evoked sympathoinhibition. Am J Physiol Heart Circ Physiol 2004; 286: H992-1000.
56. Coutts A, Pertwee R. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol 1997; 121: 1557-66.
57. Heinemann A, Shahbazian A, Holzer P. Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology 1999; 38: 1289-97.
58. Tyler K, Hillard C, Greenwood-Van M. Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. Eur J Pharmacol 2000; 409: 207-11.